SUPN at a glance
SUPERNUS PHARMACEUTICALS, INC. (SUPN, SEC CIK 1356576) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $719.0 million (up 8.6% from FY2024) and a net loss of $38.5 million. Diluted EPS was -$0.68.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding SUPERNUS PHARMACEUTICALS, INC. (SUPN) shares worth $1.4 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $719.0M
- +8.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $1.4B · −1 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 3.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: pharmaceutical development and commercialization of prescription drugs
- New emphasis on compliance with 2025 Executive Orders targeting drug price transparency, expanded Medicare negotiations, and site-neutral payment policies
- Strategic shift toward adapting to Most Favored Nation pricing model aligning U.S. drug prices with lowest prices in developed countries
- Healthcare cost containment policies expected to create pricing pressure and reimbursement reductions in 2026
- Significant regulatory risk from government efforts to accelerate generics/biosimilars and import lower-cost medicines
Risk Factors
- Legal risk from potential claims or fines related to 2021 ransomware attack, fines or costs not yet estimable
- Operational risk from increased ongoing IT security investments initiated post-2021 ransomware incident
- Cybersecurity vulnerability persists despite enhanced security measures and possibly inadequate insurance coverage
Management Discussion & Analysis
- Total revenues $718.95M, up 9% YoY from $661.82M driven by Qelbree $304.65M (+26%) and new launch ONAPGO $17.25M
- Operating loss driven by SG&A $485.56M (51% increase YoY) and intangible amortization $89.46M (+15%); net loss ($38.55M) vs net income $73.87M in 2024
- Best segment: Qelbree net sales $304.65M (+$63.38M, +26%), worst: Oxtellar XR $40.7M (-$58.76M, -59%) impacted by generic erosion
- Cash flow: Operating cash flow $47.33M (down $124.62M YoY), investing cash flow +$4.1M improvement due to acquisition funding, financing flows $9.13M; cash and equivalents $128.45M, marketable securities $180.22M
- Forward outlook: supplier constraints on ONAPGO impacting supply, regulatory approval risks for suppliers, expectation of variability in profits due to competitive pressures and patent expirations
AI summary of the SUPN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Pending Indivior merger: completion conditions may fail or face delays, potentially causing material business disruption
- Merger litigation: two New York complaints filed September 16-17, 2026, seeking injunctions and damages
- Financing risk: Indivior’s $650 million Term Loan Facility may be unavailable, forcing an Alternative Dividend
- Combined-company leverage: existing $500 million 0.625% Convertible Senior Notes due 2031 plus merger-related debt
- Fixed exchange ratio: Supernus shareholders receive 1.5401 Indivior shares regardless of stock-price changes
Management Discussion & Analysis
- Q3 revenue $226.8M, up 18% YoY from $192.1M
- Operating margin not disclosed; net loss $39.8M for nine months vs $34.4M YoY
- Best performer: ONAPGO sales $17.1M, up 151% YoY; worst: APOKYN sales $6.5M, down 38%
- Cash and securities $359.5M at September 30; operating cash flow $68.3M for nine months vs $27.5M YoY
- Outlook: cash sufficient beyond twelve months; headwinds from generic erosion, payor pressure, and potential merger-related cash reduction
AI summary of the SUPN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Merger consummated November 2, 2026, ending Supernus common stock trading on Nasdaq
- Nasdaq delisting and Section 12(b) deregistration initiated through Form 25
Item 1.01: Entry into a Material Definitive Agreement
- $650M senior secured term loan fully drawn on November 2, 2026 to fund the merger, refinance debt, transaction costs, and corporate purposes
- Initial interest: Term SOFR plus 2.25% or Base Rate plus 1.25%, at the company’s option
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material financial obligation arose from an agreement disclosed elsewhere in the filing
- Investors should review Item 1.01 for the obligation’s amount, payment terms, maturity and business purpose
Item 2.01: Completion of Acquisition or Disposition of Assets
- Supernus shareholders converted into Indivior shares at a 1.5401 exchange ratio, completing the merger
- Supernus equity awards rolled into Indivior awards, preserving existing vesting terms for RSUs and options
Item 3.03: Material Modification to Rights of Security Holders
- Supernus shareholders’ equity rights terminated at the merger’s effective time
- Each outstanding share converted into the merger consideration described under Item 2.01
Item 5.01: Changes in Control of Registrant
- Merger effective, triggering a change in control of Supernus Pharmaceuticals
- Certificate of incorporation amended and restated in full at the merger effective time
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws fully amended and restated at merger closing
- Charter documents now reflect the surviving corporation structure following the merger
Item 7.01: Regulation FD Disclosure
- Supernus announced completion of its merger, making the transaction effective for shareholders
- Combined-company structure may change Supernus’s ownership, financial reporting and strategic direction
Item EX-99.1: Item EX-99.1
- Merger completed, creating Supernus, Inc., an 11-product CNS platform spanning opioid use disorder, psychiatry, and neurology
- Former Indivior holders own 56.5% and former Supernus holders 43.5%, materially shifting ownership and governance control
Item 2.02: Results of Operations and Financial Condition
- Q3 FY2026 financial results for the quarter ended September 30, 2026 announced
- Investor focus: detailed revenue, earnings and guidance metrics in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 2026 revenue $226.8M, up 18%, with growth products revenue $192.2M, up 29%
- Qelbree sales $90.8M, up 12%, while ZURZUVAE collaboration revenue reached $41.7M, up 107%
AI summaries of SUPN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SUPN
Don't miss the next SUPN filing
- Alerts as it files. A push when SUPN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SUPN, by share count.
- Ask anything. An AI agent that reads every SUPN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Horich William Todd | J | Nov 2, 2026 | 6,250 | - |
| Sensenig Bethany | J | Nov 2, 2026 | 7,296 | - |
| Horich William Todd | J | Nov 2, 2026 | 100,000 | - |
| Horich William Todd | J | Nov 2, 2026 | 3,500 | - |
| Sensenig Bethany | J | Nov 2, 2026 | 24,153 | - |
| Sensenig Bethany | J | Nov 2, 2026 | 8,252 | - |
| Sensenig Bethany | J | Nov 2, 2026 | 4,977 | - |
| Sensenig Bethany | J | Nov 2, 2026 | 2,989 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $661.8M | $719.0M |
| Operating Income | - | $81.7M | -$62.3M |
| Net Income | $1.3M | $73.9M | -$38.5M |
| Op. Margin | - | 12.3% | -8.7% |
| Net Margin | - | 11.2% | -5.4% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.5B |
| Equity | $921.5M | $1.0B | $1.1B |
| ROE | 0.1% | 7.1% | -3.6% |
| Per Share | |||
| EPS | $0.02 | $1.32 | $-0.68 |
| Cash Flow | |||
| Operating CF | $111.1M | $172.0M | $47.3M |
| CapEx | - | $725K | $1.3M |
Source: XBRL data in SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SUPN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $1.35B |
| Q2 2026 | 30 | $1.58B |
| Q1 2026 | 30 | $1.65B |
| Q4 2025 | 28 | $1.52B |
| Q3 2025 | 28 | $1.46B |
| Q2 2025 | 29 | $893.4M |
| Q1 2025 | 26 | $620.5M |
| Q4 2024 | 23 | $594.2M |
- BlackRock+608.1K (+7%)
- Two Sigma Investments+442.0K (+37%)
- Goldman Sachs Group+295.6K (+36%)
- Morgan Stanley+294.1K (+34%)
- State Street Corp+109.3K (+4%)
- Millennium Management−1.88M (-49%)
- Citadel Advisors LLC−545.1K (-40%)
- Renaissance Technologies LLC−346.6K (-23%)
- Dimensional Fund Advisors−235.8K (-11%)
- D.E. Shaw & Co−207.1K (-27%)
- FMR LLC (Fidelity)−309.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SUPN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 19, 2026 | - | Analysis | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SUPN SEC filings: frequently asked questions
Which institutions hold SUPN stock?
As of September 30, 2026, the largest SUPERNUS PHARMACEUTICALS, INC. (SUPN) holders among the 13F filers tracked by SignalX were BlackRock ($428.6 million), Vanguard Portfolio Management LLC ($141.4 million), State Street Corp ($110.6 million), Vanguard Capital Management LLC ($108.6 million), Millennium Management ($84.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SUPN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $719.0 million (up 8.6% from FY2024) and a net loss of $38.5 million. Diluted EPS was -$0.68. The figures come from the XBRL data in the 10-K.
What are the main risks in SUPN's latest 10-K?
In the 10-K filed March 2, 2026, SUPERNUS PHARMACEUTICALS, INC. (SUPN) flagged: Legal risk from potential claims or fines related to 2021 ransomware attack, fines or costs not yet estimable. Operational risk from increased ongoing IT security investments initiated post-2021 ransomware incident. (AI summary of the Risk Factors section.)
What did SUPN report in its latest 8-K?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K on November 2, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Merger consummated November 2, 2026, ending Supernus common stock trading on Nasdaq.
What are the latest SUPN SEC filings?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 4, 2026.
What is SUPN's SEC CIK number?
SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s SEC Central Index Key (CIK) is 1356576. EDGAR lists every SUPN filing under that number.
Ask anything about SUPN
The research agent reads SUPN's filings, financials, insider trades and 13F holders, then answers with sources.